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Patients With Chronic Kidney Disease
What Explains the Magic?*John A. Bittl, MDR andomized, controlled trials (RCTs) com-paring percutaneous coronary intervention(PCI) with coronary artery bypass graft
(CABG) surgery for multivessel coronary artery disease
(CAD) have routinely excluded patients with chronic
kidney disease (CKD), so decisions about revasculari-
zation in this population depend on other sources of
evidence (1). Several observational studies have re-
ported that patients with CKD or end-stage renal dis-
ease requiring hemodialysis had higher mortality
rates after PCI than after CABG for multivessel CAD
(2,3), resulting in clinical guidelines favoring surgical
therapy over PCI for this population of patients (4).SEE PAGE 1209A new observational study reported in this issue of
the Journal (5) found that patients with CKD stage III
or IV with estimated glomerular ﬁltration rates ofw15
to 60 ml/min who had undergone PCI for multivessel
CAD with everolimus-eluting stents (EES) had lower
short-term mortality rates (1.0% vs. 1.7% at 30 days;
hazard ratio [HR]: 0.55; 95% conﬁdence interval [CI]:
0.35 to 0.87), and long-term mortality rates that were
no different (22.7% vs. 20.5% at 2.9 years; HR: 1.07;
95% CI: 0.92 to 1.24), than those of patients who had
undergone CABG. For the group with CKD stage 5 on
hemodialysis, however, the study found that patients
treated with EES had higher long-term mortality
rates (54.3% vs. 39.1%; HR: 2.02; 95% CI: 1.40 to 2.93)
than did patients treated with CABG.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of the JACC or the American College of Cardiology.
From the Munroe Regional Medical Center, Ocala, Florida. Dr. Bittl has
reported that he has no relationships relevant to the contents of this
paper to disclose.Because the current study is a rigorous analysis (5),
a ﬁnding of a narrowed mortality difference between
PCI and CABG for patients with CKD stage III or IV is
newsworthy. To put the results of the study into
perspective and understand how implantation of an
EES could improve the survival of patients with CKD,
I review emerging information about the vasculop-
athy associated with CKD and new evidence of the
primacy of EES implantation in PCI.
Vascular calciﬁcation is pervasive in CKD. Impaired
renal excretion of phosphate (Pi) may trigger the
formation of macrophage-derived matrix vesicles that
facilitate hydroxyapatite nucleation, contributing to
vascular microcalciﬁcation (6). Separate from spotty
calciﬁcation in the intima, which may predispose
the vulnerable atherosclerotic plaque to rupture (7),
conﬂuent medial calciﬁcation is the vascular hallmark
of CKD.
Medial calciﬁcation develops through a mechanism
analogous to bone formation and occurs in CKD in-
dependently of the traditional risk factors of dia-
betes, hypertension, and hyperlipidemia (8). Recent
evidence suggests that extracellular Pi is transported
into vascular smooth-muscle cells by a sodium Pi
cotransporter, and the resultant increase in intracel-
lular Pi induces the cells to adopt the genetic and
cellular properties of osteoblasts (9). Bone disease in
CKD worsens vascular calciﬁcation. High bone turn-
over ensures a continuous source of mineral, and low-
turnover disease acts like osteoporosis in which
demineralization of bone is associated with minerali-
zation of the vascular wall (8).
Pi binders are designed to reduce Pi, but calcium-
containing binders like calcium acetate theoretically
exacerbate vascular calciﬁcation, particularly when
they are used with vitamin D (10). The calcium-free
binder sevelamer has been increasingly replacing
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1222calcium-containing binders in clinical practice, but
there is little evidence that sevelamer improves
mortality or reduces vascular calciﬁcation (11).
In addition to causing calciﬁcation, CKD may
change the pattern of CAD. In an angiographic study,
investigators found that patients with CKD were more
likely than patients without CKD to have signiﬁcant
lesions within the proximal segments of the coronary
arteries (12).
Given the vascular ﬁndings, discerning readers
may wish to understand how “spot” stenting of pre-
dominantly calciﬁed lesions often located in the
proximal segments of the coronary tree in patients
with CKD could lead to favorable clinical outcomes
compared with other forms of revascularization. For
many interventional cardiologists, lesion calciﬁcation
might elicit the use of adjunctive ablative therapies,
but a serum creatinine level >2.5 mg/dl has been a
common exclusion in RCTs of orbital and rotational
atherectomy (13), giving little guidance for the CKD
population.
The development of EES has been a major
advance in PCI. Recent evidence suggests that EES
are associated with lower stent-thrombosis and all-
cause mortality rates than are bare metal or ﬁrst-
generation drug-eluting stents (14). Although lower
EES-related complications may be attributed to
better strut coverage or lower inﬂammation (15),
the mechanisms cannot explain how EES perform
better than other types of stents in calciﬁed lesions
or how EES could compete with surgical conduits
to protect against future atherothrombotic events
in long segments of the coronary tree in patients
with CKD.
The current study (5) has many strengths, but an
observational study is not likely to reveal pathoge-
netic mechanisms. The study compared outcomes in
patients whose referral for EES implantation or CABG
was selected but not randomly assigned. Similar to
patients enrolled in other studies (2), patients
referred for stent implantation in the current studywere less likely than those referred for CABG to have
3-vessel disease or multivessel CAD involving the
proximal left anterior descending (LAD) artery.
To even out the systematic differences between the
EES and the CABG groups, Bangalore et al. (5) used
propensity-score matching, but some experts argue
that no adjustment can eliminate prognostic imbal-
ances when different patients are selected for
different therapies (16).
A major strength of the current study (5) is its
exclusive focus on the use of EES. The study thus
gives relevant and timely guidance for revasculari-
zation decisions in patients with CKD and multivessel
CAD. The results suggest that patients with CKD stage
III or IV and multivessel CAD can undergo EES im-
plantation as an alternative to CABG, particularly if
there are mitigating factors against CABG such as
frailty or signiﬁcantly reduced life expectancy. How-
ever, surgical candidates with CKD stage III or IV and
multivessel CAD involving the proximal LAD should
probably be given the option of CABG because longer
follow-up may show a survival advantage with sur-
gery. Although a subset analysis in the report (5)
suggests that patients on hemodialysis should un-
dergo CABG in preference to PCI, revascularization
decisions for patients with CKD stage V are compli-
cated and must be individualized. Finally, the
current study throws down the gauntlet for in-
vestigators to design a dedicated RCT comparing
PCI with CABG for patients with CKD (1) and for
experimental studies to continue to identify the
pathogenetic links between the metabolic de-
rangements of CKD and vasculopathy to codify best
practices and to provide new insights into mecha-
nisms of success of EES in the challenging milieu of
CKD vasculopathy.
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